US Stock MarketDetailed Quotes
VRAX Virax Biolabs
- 1.7000
- -0.1100-6.08%
Close Oct 15 16:00 ET
- 1.6402
- -0.0598-3.52%
Post 20:02 ET
7.38MMarket Cap-505P/E (TTM)
1.8400High1.6800Low160.72KVolume1.8200Open1.8100Pre Close278.23KTurnover3.96%Turnover RatioLossP/E (Static)4.34MShares8.999952wk High1.38P/B6.89MFloat Cap0.600052wk Low--Dividend TTM4.05MShs Float290.0000Historical High--Div YieldTTM8.84%Amplitude0.6000Historical Low1.7310Avg Price1Lot Size
Virax Biolabs Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | |
|---|---|---|---|---|---|
| Total revenue | 1,727.11%156.42K | 8.56K | 0 | 23.97%123.82K | 99.88K |
| Operating revenue | 1,727.11%156.42K | --8.56K | --0 | 23.97%123.82K | --99.88K |
| Cost of revenue | 966.18%105.83K | 9.93K | 0 | 146.19%133.25K | 54.13K |
| Gross profit | 3,806.23%50.59K | -1.37K | 0 | -120.62%-9.43K | 45.75K |
| Operating expense | 7.42%6.16M | 230.59%5.73M | 172.98%1.73M | -8.88%635.1K | 696.99K |
| Selling and administrative expenses | 29.35%4.59M | 173.25%3.55M | 152.47%1.3M | -15.59%514.88K | --609.99K |
| -Selling and marketing expense | ---- | ---- | ---- | 643.86%57.2K | --7.69K |
| -General and administrative expense | 29.35%4.59M | 173.25%3.55M | 184.03%1.3M | -24.01%457.68K | --602.3K |
| Research and development costs | -28.33%1.56M | 402.45%2.18M | 260.79%433.74K | 38.19%120.22K | --87K |
| Operating profit | -6.51%-6.11M | -230.67%-5.73M | -168.98%-1.73M | 1.03%-644.54K | -651.24K |
| Net non-operating interest income expense | -73.77%-26.88K | -0.19%-15.47K | 46.10%-15.44K | 68.42%-28.64K | -90.69K |
| Non-operating interest expense | 73.77%26.88K | 0.19%15.47K | -46.10%15.44K | -68.42%28.64K | --90.69K |
| Other net income (expense) | -308.67%-606.12K | 38,674.50%290.47K | -383.08%-753 | -89.23%266 | 2.47K |
| Special income (charges) | ---390.36K | --0 | --0 | ---- | ---- |
| -Less:Impairment of capital assets | --390.36K | --0 | --0 | ---- | ---- |
| Other non- operating income (expenses) | -174.28%-215.77K | 38,674.50%290.47K | -383.08%-753 | -89.23%266 | --2.47K |
| Income before tax | -23.48%-6.74M | -211.90%-5.46M | -160.04%-1.75M | 9.00%-672.92K | -739.46K |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | -23.48%-6.74M | -211.90%-5.46M | -160.04%-1.75M | 9.00%-672.92K | -739.46K |
| Net income continuous Operations | -23.48%-6.74M | -211.90%-5.46M | -160.04%-1.75M | 9.00%-672.92K | ---739.46K |
| Minority interest income | -1,975.46%-5.58K | 99.34%-269 | -87.15%-41.04K | 24.44%-21.93K | -29.02K |
| Net income attributable to the parent company | -23.38%-6.73M | -219.37%-5.46M | -162.50%-1.71M | 8.37%-650.98K | -710.44K |
| Preferred stock dividends | |||||
| Other preferred stock dividends | |||||
| Net income attributable to common stockholders | -23.38%-6.73M | -219.37%-5.46M | -162.50%-1.71M | 8.37%-650.98K | -710.44K |
| Basic earnings per share | -554.97%-3.36 | 65.85%-0.513 | -162.50%-1.5024 | 8.37%-0.5723 | -0.6246 |
| Diluted earnings per share | -554.97%-3.36 | 65.85%-0.513 | -162.50%-1.5024 | 8.37%-0.5723 | -0.6246 |
| Dividend per share | |||||
| Currency Unit | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
